How does frailty impact the efficacy, reactogenicity, immunogenicity and safety of the adjuvanted recombinant zoster vaccine? A secondary analysis of the ZOE-50 and ZOE-70 studies
Publication
, Conference
Weller, R; Andrew, MK; Kim, JH; Matthews, S; Dessart, C; Levin, MJ; Oostvogels, L; Riley, M; Schmader, KE; Mcneil, SA; Schuind, AE; Curran, D
Published in: INTERNIST
2021
Duke Scholars
Published In
INTERNIST
EISSN
1432-1289
ISSN
0020-9554
Publication Date
2021
Volume
62
Issue
SUPPL 2
Start / End Page
168 / 168
Related Subject Headings
- General & Internal Medicine
- 3202 Clinical sciences
- 1103 Clinical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Weller, R., Andrew, M. K., Kim, J. H., Matthews, S., Dessart, C., Levin, M. J., … Curran, D. (2021). How does frailty impact the efficacy, reactogenicity, immunogenicity and safety of the adjuvanted recombinant zoster vaccine? A secondary analysis of the ZOE-50 and ZOE-70 studies. In INTERNIST (Vol. 62, pp. 168–168).
Weller, Romy, Melissa K. Andrew, Joon Hyung Kim, Sean Matthews, Christophe Dessart, Myron J. Levin, Lidia Oostvogels, et al. “How does frailty impact the efficacy, reactogenicity, immunogenicity and safety of the adjuvanted recombinant zoster vaccine? A secondary analysis of the ZOE-50 and ZOE-70 studies.” In INTERNIST, 62:168–168, 2021.
Weller R, Andrew MK, Kim JH, Matthews S, Dessart C, Levin MJ, et al. How does frailty impact the efficacy, reactogenicity, immunogenicity and safety of the adjuvanted recombinant zoster vaccine? A secondary analysis of the ZOE-50 and ZOE-70 studies. In: INTERNIST. 2021. p. 168–168.
Weller, Romy, et al. “How does frailty impact the efficacy, reactogenicity, immunogenicity and safety of the adjuvanted recombinant zoster vaccine? A secondary analysis of the ZOE-50 and ZOE-70 studies.” INTERNIST, vol. 62, no. SUPPL 2, 2021, pp. 168–168.
Weller R, Andrew MK, Kim JH, Matthews S, Dessart C, Levin MJ, Oostvogels L, Riley M, Schmader KE, Mcneil SA, Schuind AE, Curran D. How does frailty impact the efficacy, reactogenicity, immunogenicity and safety of the adjuvanted recombinant zoster vaccine? A secondary analysis of the ZOE-50 and ZOE-70 studies. INTERNIST. 2021. p. 168–168.
Published In
INTERNIST
EISSN
1432-1289
ISSN
0020-9554
Publication Date
2021
Volume
62
Issue
SUPPL 2
Start / End Page
168 / 168
Related Subject Headings
- General & Internal Medicine
- 3202 Clinical sciences
- 1103 Clinical Sciences